Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …

Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …

Background Clinical trials have shown that trastuzumab, a recombinant monoclonal
antibody against HER2 receptor, significantly improves overall survival and disease-free …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Accumulating data suggest that metastatic dissemination often occurs early during tumour
formation, but the mechanisms of early metastatic spread have not yet been addressed …

In 2012, the estimated age-adjusted annual incidence of breast cancer in 40 European
countries was 94.2/100 000 and the mortality 23.1/100 000 [1]. The incidence increased …

Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4,
has clinical activity in patients with HER2-positive metastatic breast cancer. We aimed to …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …